The hearing loss treatment developer has filed to raise up to $100m, three months after a $105m round featuring Novartis, Partners HealthCare and Pivotal BioVenture Partners.
US-based genetic medicine developer Akouos has filed for a $100m initial public offering on the Nasdaq Global Market, setting up pharmaceutical firm Novartis and healthcare provider Partners HealthCare for exits.
Founded in 2016, Akouos is developing precision gene therapies to combat the most common form of hearing loss, which is caused by inner ear disorders. Its lead asset, AK-OTOF, is aimed at hearing loss caused by mutations in the otoferlin (OTOF) gene.
Proceeds from the IPO would go to…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
